Monitor upcoming clinical trial data readouts for Acclaim-1 and Acclaim-3 trials, as positive biomarker research could enhance patient selection and improve trial outcomes.
Price Chart
Executive Summary
Genprex announced a new Sponsored Research Agreement with MD Anderson Cancer Center to study biomarkers TROP2 and PTEN for its lead drug candidate Reqorsa. The company also highlighted positive clinical trial results from its Acclaim-1 and Acclaim-3 trials, showing prolonged progression-free survival and partial responses in some patients.
Key Facts
- Genprex entered a new Sponsored Research Agreement with MD Anderson Cancer Center to study biomarkers TROP2 and PTEN for its lead drug candidate Reqorsa
- Research aims to refine patient selection strategies for Acclaim-1 and Acclaim-3 clinical trials
- Acclaim-1 trial showed prolonged progression-free survival in 3 out of 12 patients, with one patient maintaining partial remission for 42 months
- Acclaim-3 trial showed one patient achieved unconfirmed partial remission after 18 months of treatment
- The research collaboration has been ongoing since 2010 with several completed agreements
Financial Impact
No financial impact disclosed
Risk Factors
- Clinical trial results are still in early stages with limited patient data
- Biomarker research may not lead to improved patient outcomes
- Small biotech with $10M market cap faces high execution risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-012879 |
| Document: gnpx20260329_8k.htm | 0001437749-26-012879 |
| Document: 0001437749-26-012879-index-headers.html | 0001437749-26-012879 |
| Document: 0001437749-26-012879-index.html | 0001437749-26-012879 |
| Document: 0001437749-26-012879.txt | 0001437749-26-012879 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 6d ago | 8-K | $2.05 | awaiting T+60 | — | $1.91 (−6.76%) |
Aug 18, 2026 10w ago | 8-K | $3.95 | awaiting T+60 | — | $1.91 (−51.61%) |
Aug 3, 2026 12w ago | 8-K | $4.75 | awaiting T+60 | — | $1.91 (−59.76%) |
Jul 14, 2026 15w ago | 8-K | $0.4632 $0.1191 | ▲ +74.29% | ▲ +77.67% | $1.91 (−312.65%) |
Jun 22, 2026 18w ago | 8-K | $0.5501 $0.1550 | ▼ −71.82% | ▼ −73.12% | $1.91 (+247.46%) |
May 26, 2026 22w ago | 8-K | $16.98 $3.99 | ▼ −76.51% | ▼ −79.23% | $1.91 (−88.75%) |
May 14, 2026 23w ago | 8-K | $18.94 $4.19 | ▼ −77.88% | ▼ −81.47% | $1.91 (−89.91%) |
Apr 28, 2026 26w ago | 8-K | $20.35 $7.49 | ▼ −63.19% | ▼ −67.18% | $1.91 (−90.61%) |
Apr 21, 2026 27w ago | 8-K | $23.98 $7.67 | ▼ −68.02% | ▼ −73.86% | $1.91 (−92.03%) |
Mar 18, 2026 31w ago | 8-K | $2.01 $0.6540 | ▼ −67.46% | ▼ −78.99% | $1.91 (−4.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers